Verrica Pharmaceuticals Management

Management criteria checks 2/4

Verrica Pharmaceuticals' CEO is Ted White, appointed in Dec 2017, has a tenure of 6.33 years. total yearly compensation is $3.50M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €591.11K. The average tenure of the management team and the board of directors is 4.5 years and 5.9 years respectively.

Key information

Ted White

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage	17.1%
CEO tenure	6.3yrs
CEO ownership	0.2%
Management average tenure	4.5yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ted White's remuneration changed compared to Verrica Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$4m	US$601k	-US$67m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$23m
Dec 31 2022	US$2m	US$572k	-US$24m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$41m
Mar 31 2022	n/a	n/a	-US$43m
Dec 31 2021	US$2m	US$550k	-US$35m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$36m
Mar 31 2021	n/a	n/a	-US$34m
Dec 31 2020	US$2m	US$485k	-US$43m
Sep 30 2020	n/a	n/a	-US$37m
Jun 30 2020	n/a	n/a	-US$33m
Mar 31 2020	n/a	n/a	-US$31m
Dec 31 2019	US$1m	US$433k	-US$28m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$5m	US$400k	-US$21m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$24k	US$24k	-US$10m

Compensation vs Market: Ted's total compensation ($USD3.50M) is above average for companies of similar size in the German market ($USD678.96K).

Compensation vs Earnings: Ted's compensation has increased whilst the company is unprofitable.

CEO

Ted White (58 yo)

6.3yrs

Tenure

US$3,504,647

Compensation

Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ted White	President	6.3yrs	US$3.50m	0.22% $ 591.1k
Christopher Hayes	Chief Legal Officer	5.6yrs	US$2.56m	0.055% $ 144.4k
Joe Bonaccorso	Chief Commercial Officer	6.2yrs	US$2.10m	0.012% $ 30.4k
P. Terence Kohler	Chief Financial Officer	2.8yrs	no data	0.081% $ 213.9k
Gary Goldenberg	Chief Medical Officer	3.8yrs	US$989.18k	0.10% $ 264.2k
Eugene Scavola	Executive Vice President of Technical Operations	4.5yrs	no data	no data
Bradley Catalone	Head of Drug Development	3.7yrs	no data	no data

4.5yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 1NE's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ted White	President	5.9yrs	US$3.50m	0.22% $ 591.1k
Mark Prygocki	Independent Director	5.9yrs	US$119.19k	0% $ 0
Mark Lebwohl	Member of Scientific Advisory Board	no data	no data	no data
Lawrence F. Eichenfield	Independent Director	3.8yrs	US$119.19k	0% $ 0
Sean Stalfort	Director	8.3yrs	no data	1.65% $ 4.4m
Paul Manning	Chairman of the Board	8.3yrs	no data	36.15% $ 95.3m
Craig Ballaron	Independent Director	4.8yrs	US$119.19k	0.024% $ 62.2k
Steven Cohen	Member of Scientific Advisory Board	no data	no data	no data
Elaine Siegfried	Member of Scientific Advisory Board	no data	no data	no data
Anthony Mancini	Member of Scientific Advisory Board	no data	no data	no data
Janice Pelletier	Member of Scientific Advisory Board	no data	no data	no data
Robert Greenberg	Member of Scientific Advisory Board	no data	no data	no data

5.9yrs

Average Tenure

60yo

Average Age

Experienced Board: 1NE's board of directors are considered experienced (5.9 years average tenure).

Verrica Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Chief Financial Officer recently sold €76k worth of stock

Insufficient new directors

Chairman of the Board recently bought €907k worth of stock

Director recently bought €488k worth of stock

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Recent updates

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Forecast to breakeven in 2026

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$1.48 loss per share (vs US$0.72 loss in FY 2022)

Verrica Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services

Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™? for the Treatment of Common Warts

Forecast to breakeven in 2026

Chief Financial Officer recently sold €76k worth of stock

New minor risk - Profitability

New minor risk - Profitability

Verrica Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2022)

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting

Insufficient new directors

Chairman of the Board recently bought €907k worth of stock

New major risk - Share price stability

Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Forecast to breakeven in 2025

No longer forecast to breakeven

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.31 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$0.72 loss per share (vs US$1.30 loss in FY 2021)

Forecast to breakeven in 2025

Verrica Pharmaceuticals Inc. Resubmits New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.47 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.43 loss in 2Q 2021)

Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Director recently bought €488k worth of stock

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $25.2 million.

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell 2000 Growth Index

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc

No longer forecast to breakeven

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Verrica Pharmaceuticals Inc. Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-In-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

No longer forecast to breakeven

Forecast to breakeven in 2024

Verrica Pharmaceuticals Inc. Announces Acceptance by FDA of NDA Resubmission for VP-102

Chairman of the Board recently bought €415k worth of stock

Verrica Pharmaceuticals Inc. Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Receives Complete Response Letter from the FDA Identifying Deficiencies At Facility of Contract Manufacturer for Its New Drug Application for Vp-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Inc. Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts

Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP 102 in Patients with Common Warts

JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age